Clinical trials: Mask
Diabetic Retinopathy
A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI).
- Trial name
- NCT05038020
- Testing
- AKST4290
- Where
- 17 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alkahest, Inc.
Bacterial Conjunctivitis
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with bacterial conjunctivitis.
- Trial name
- NCT03004924
- Testing
- SHP640, PVP-I 0.6%
- Where
- 163 sites in United States, Australia and 11 more
- Volunteers
- 753 people
- Sponsor
- Shire
Open-Angle Glaucoma, Ocular Hypertension
A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to demonstrate equivalent safety and IOP-lowering effectiveness of two Travoprost/Timolol combination products in patients diagnosed with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00672997
- Testing
- Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, Travoprost 0.004%/Timolol 0.5% ophthalmic solution
- Volunteers
- 301 people
- Sponsor
- Alcon Research
Mesopic Vision, Night Vision Loss
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.
- Trial name
- LYNX-2 (NCT06349759)
- Testing
- phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Opus Genetics, Inc
Blepharitis
Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study
The Phase III main study is a randomized, controlled, multicenter, double blind, trial to evaluate the efficacy and safety of TP-03 (lotilaner ophthalmic solution, 0.25%), for the treatment of Demodex blepharitis in Chinese…
- Trial name
- NCT05629390
- Testing
- Lotilaner, Vehicle Control
- Where
- 21 sites in China
- Volunteers
- 163 people
- Sponsor
- LianBio LLC
Sturge-Weber Syndrome (SWS), Glaucoma
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).
- Conditions
- Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
- Trial name
- NCT04947124
- Testing
- QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Qlaris Bio, Inc.
Musculoskeletal Pain
Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine in Osteomuscular Treatment
The purpose of this study is to evaluate the safety and efficacy of an association with one anti-inflammatory and one muscle relaxant agent compared to the one muscle relaxant agent isolated in the treatment of osteomuscular pain…
- Trial name
- NCT03025113
- Testing
- ketoprofen and cyclobenzaprine association, Cyclobenzaprine
- Where
- Brazil
- Volunteers
- 416 people
- Sponsor
- EMS
Allergic Conjunctivitis
Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis
- Trial name
- NCT00364091
- Testing
- R89674 0.025% ophthalmic solution
- Where
- 6 sites in United States
- Volunteers
- 365 people
- Sponsor
- Vistakon Pharmaceuticals
Dry Eye Syndrome
Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
The purpose of this study was to determine if Sodium Hyaluronate, 0.18% is effective in treating the signs and symptoms of dry eye disease.
- Trial name
- NCT01382225
- Testing
- Sodium Hyaluronate Ophthalmic Solution, 0.18%, Vehicle
- Volunteers
- 1,936 people
- Sponsor
- Alcon Research
Inflammation Associated With Cataract Surgery
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.
- Trial name
- NCT01606735
- Testing
- IBI-10090
- Where
- 2 sites in United States
- Volunteers
- 172 people
- Sponsor
- ICON Bioscience Inc
Dry Age-related Macular Degeneration, Geographic Atrophy
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.
- Trial name
- NCT01002950
- Testing
- ACU-4429
- Where
- 12 sites in United States
- Volunteers
- 72 people
- Sponsor
- Kubota Vision Inc.
Ophthalmology, Photorefractive Keratectomy ("PRK")
Ocular Bandage Gel (OBG) Pivotal Trial in Patients Undergoing Photorefractive Keratectomy ("PRK")
Prospective, randomized, masked (reading center), controlled pivotal study of Ocular Bandage Gel (OBG) vs. a bandage contact lens (BCL) in subjects who have undergone bilateral photorefractive keratectomy (PRK).
- Conditions
- Ophthalmology, Photorefractive Keratectomy ("PRK"), Laser Assisted Surgery, Refractive Surgery
- Trial name
- NCT03938883
- Testing
- Ocular Bandage Gel (OBG), Bandage Contact Lens (BCL)
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Healhty
Study to Evaluate Safety, Tolerability and Pharmacokinetics of G01 Eye Drops in Healthy Volunteers
The primary objective of this study is to assess the safety and tolerability of single and multiple ascending doses of G01 when administered as eye drops in healthy subjects.
- Trial name
- NCT07779902
- Testing
- G01 Eye Drops 100 µg/mL SAD, G01 Eye Drops 200 µg/mL SAD, G01 Eye Drops 400 µg/mL SAD
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Glaucoma, Open-Angle, Hypertension, Ocular
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT03657797
- Testing
- NCX 470, Latanoprost 0.005%
- Where
- United States
- Volunteers
- 656 people
- Sponsor
- Nicox Ophthalmics, Inc.
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
- Trial name
- ENDURE (NCT01032915)
- Testing
- AIN457
- Where
- 94 sites in United States, Brazil and 8 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease
Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Clinical Trial Evaluating the Safety and Tolerability of ALY688 in Subjects with Dry Eye Disease
- Trial name
- NCT04201574
- Testing
- ALY688 0.1%, ALY688 0.4%, Vehicle
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Allysta Pharmaceutical
Elevated Intraocular Pressure
Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure
Prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TearClear latanoprost Ophthalmic Solution, 0.005% (TC-002) compared to…
- Trial name
- TC-002-301 (NCT05165290)
- Testing
- Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- TearClear Corp
Dry Eye
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months
- Trial name
- NCT06565650
- Testing
- Miebo, Saline
- Where
- 12 sites in United States
- Volunteers
- 216 people
- Sponsor
- Bausch & Lomb Incorporated
Open Angle Glaucoma, Ocular Hypertension
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia
PhXA41 is not inferior to timolol in reducing intra-ocular pressure
- Trial name
- NCT00751062
- Testing
- timolol, PhXA41
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Allergic Conjunctivitis
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC…
- Trial name
- NCT05265910
- Testing
- olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Andover Research Eye Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.